Welcome to our dedicated page for BRII BIOSCIENCES news (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on BRII BIOSCIENCES stock.
Brii Biosciences Limited reports biotechnology developments centered on chronic hepatitis B functional-cure programs and anti-infective assets. Company news commonly covers clinical data from HBV combination studies, including elebsiran, an HBV-targeting siRNA, and BRII-179, a recombinant protein-based HBV immunotherapeutic designed to induce broad B-cell and T-cell immunity.
Updates also address corporate results, intellectual-property rights for BRII-179, regulatory interactions related to HBV development, and partnership activity for infectious-disease candidates. Brii Bio's anti-infective coverage includes BRII-693, also known as soralimixin, and collaboration or licensing activity tied to development and commercialization in Greater China.
Brii Biosciences has acquired exclusive development and commercialization rights for VIR-3434 (BRII-877) in Greater China. This strategic move enhances its clinical pipeline targeting Hepatitis B virus (HBV) and enables diverse combination treatment options. VIR-3434 is a monoclonal antibody currently in Phase 2 development. Brii's partnership with Vir Biotechnology strengthens its HBV initiatives as they explore various treatment combinations. The agreement includes milestone and royalty payments based on net sales, with rates ranging from 15% to 25%.